Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Starting patients on two IV antibiotics early may be the key to clearing dangerous staph bloodstream infections faster. A new clinical trial found dual therapy significantly cut the duration of S. aureus bacteremia compared to standard single-drug treatment — though it didn't budge mortality rates. Experts say the findings are promising but not yet enough to fully shift practice.
A preliminary clinical trial presented at IDWeek 2026 suggests that hitting Staphylococcus aureus bacteremia with two IV antibiotics from the start — rather than the traditional single-drug approach — significantly shortens how long the infection lingers in the bloodstream. Researchers from West Virginia University called for a "paradigm shift" in how this deadly infection is managed.
The open-label, randomized trial enrolled 193 patients across six rural hospitals. Patients in the dual-therapy group received either daptomycin/ceftaroline or cefazolin/ertapenem, while the control group got standard single-drug IV therapy. The study also found that switching to oral antibiotics after 3 days of negative blood cultures was safe, and relapse rates were low.
By the Numbers:
Why it matters: S. aureus bacteremia carries a mortality rate as high as 40%, making faster clearance a meaningful clinical goal. While dual therapy didn't reduce deaths, getting patients off IV antibiotics sooner could cut hospital stays and complications — a win worth watching, even if experts aren't fully aligned yet.
